M-CINACALCET 30 MG
CINACALCET (CINACALCET HYDROCHLORIDE) : 30 MG · DIN 02481987 · MANTRA PHARMA INC
Health Canada status: MARKETED
What is M-CINACALCET?
M-CINACALCET 30 MG contains CINACALCET (CINACALCET HYDROCHLORIDE) : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02481987, held by MANTRA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Dec-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is M-CINACALCET used for?
Secondary hyperparathyroidism in CKD patients on dialysis; hypercalcemia in patients with parathyroid carcinoma; hypercalcemia in primary HPT where parathyroidectomy is inappropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02481987 |
|---|---|
| Brand name | M-CINACALCET |
| Generic / active ingredient | CINACALCET (CINACALCET HYDROCHLORIDE) : 30 MG |
| Manufacturer | MANTRA PHARMA INC |
| Strength | 30 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | H05BX01 CINACALCET |
| AHFS class | 92:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Dec-2018 |
| Original market date | 2018-12-11 00:00:00 |
How is it administered?
Secondary HPT: Start 30 mg once daily, titrate every 2-4 weeks (max 180 mg/day). Parathyroid Carcinoma/Primary HPT: Start 30 mg twice daily, titrate every 2-4 weeks. Take with food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists section 15, but text ends at section 14).
How is it supplied?
Not explicitly detailed in provided text (mentions 30 mg, 60 mg, 90 mg strengths).
Contraindications
Hypersensitivity to any components; should not be initiated if serum calcium (corrected for albumin) is below the lower limit of the normal range.
Warnings and precautions
Risk of hypocalcemia (monitor serum calcium); QT prolongation and ventricular arrhythmias; seizures (threshold lowered by hypocalcemia); adynamic bone disease if iPTH < 11.0 pmol/L.
What can be used instead?
Other Canadian products sharing ATC code H05BX01 CINACALCET. 22 of 45 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CINACALCET | 30 MG | TABLET | APOTEX INC | MARKETED | DIN 02452693 |
| APO-CINACALCET | 60 MG | TABLET | APOTEX INC | MARKETED | DIN 02452707 |
| APO-CINACALCET | 90 MG | TABLET | APOTEX INC | MARKETED | DIN 02452715 |
| AURO-CINACALCET | 30 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02478900 |
| AURO-CINACALCET | 60 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02478919 |
| AURO-CINACALCET | 90 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02478943 |
| CINACALCET | 30 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02524880 |
| JAMP CINACALCET TABLETS | 30 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02500094 |
| JAMP CINACALCET TABLETS | 60 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02500108 |
| JAMP CINACALCET TABLETS | 90 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02500116 |
Who else supplies CINACALCET worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CINACALCET appears in 814 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.